MEIP
Price:
$3.1
Market Cap:
$20.65M
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical tr...[Read more]
Industry
Biotechnology
IPO Date
2003-12-18
Stock Exchange
NASDAQ
Ticker
MEIP
According to MEI Pharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 0.79. This represents a change of -228.08% compared to the average of -0.62 of the last 4 quarters.
The mean historical PE Ratio of MEI Pharma, Inc. over the last ten years is -0.73. The current 0.79 PE Ratio has changed -10867.35% with respect to the historical average. Over the past ten years (40 quarters), MEIP's PE Ratio was at its highest in in the September 2020 quarter at 7.17. The PE Ratio was at its lowest in in the March 2017 quarter at -20.25.
Average
-0.73
Median
-3.15
Minimum
-10.66
Maximum
33.06
Discovering the peaks and valleys of MEI Pharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 161.63%
Maximum Annual PE Ratio = 33.06
Minimum Annual Increase = -1583.03%
Minimum Annual PE Ratio = -10.66
Year | PE Ratio | Change |
---|---|---|
2023 | -1.38 | -0.73% |
2022 | -1.39 | -78.12% |
2021 | -6.34 | -22.43% |
2020 | -8.17 | -23.31% |
2019 | -10.66 | 161.63% |
2018 | -4.07 | -112.32% |
2017 | 33.06 | -1583.03% |
2016 | -2.23 | 51.24% |
2015 | -1.47 | -68.54% |
2014 | -4.69 | -27.36% |
The current PE Ratio of MEI Pharma, Inc. (MEIP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.04
5-year avg
-5.59
10-year avg
-0.73
MEI Pharma, Inc.’s PE Ratio is greater than Magenta Therapeutics, Inc. (-0.04), greater than Kezar Life Sciences, Inc. (-0.41), greater than Vincerx Pharma, Inc. (-0.95), greater than Avenue Therapeutics, Inc. (-0.31), greater than Assembly Biosciences, Inc. (-2.10), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Instil Bio, Inc. (-0.78), less than CytomX Therapeutics, Inc. (9.19), greater than Achilles Therapeutics plc (-0.45), greater than Ocular Therapeutix, Inc. (-10.06), less than Spero Therapeutics, Inc. (4.06), greater than Acumen Pharmaceuticals, Inc. (-2.06), greater than HOOKIPA Pharma Inc. (-1.22), greater than Day One Biopharmaceuticals, Inc. (-7.39), greater than Inozyme Pharma, Inc. (-3.48), greater than Terns Pharmaceuticals, Inc. (-6.06), greater than Revelation Biosciences, Inc. (-0.09), greater than Zura Bio Limited (-9.00), greater than Phio Pharmaceuticals Corp. (-0.15), greater than ZyVersa Therapeutics, Inc. (-0.10), greater than TransCode Therapeutics, Inc. (-0.10),
Company | PE Ratio | Market cap |
---|---|---|
-0.04 | $42.44M | |
-0.41 | $40.82M | |
-0.95 | $22.05M | |
-0.31 | $4.05M | |
-2.10 | $107.81M | |
-0.98 | $8.20M | |
-0.78 | $92.68M | |
9.19 | $93.74M | |
-0.45 | $29.58M | |
-10.06 | $1.31B | |
4.06 | $71.07M | |
-2.06 | $133.38M | |
-1.22 | $159.50M | |
-7.39 | $1.25B | |
-3.48 | $312.42M | |
-6.06 | $549.60M | |
-0.09 | $1.43M | |
-9.00 | $230.86M | |
-0.15 | $2.25M | |
-0.10 | $2.70M | |
-0.10 | $4.56M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MEI Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MEI Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is MEI Pharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for MEI Pharma, Inc. (MEIP)?
What is the highest PE Ratio for MEI Pharma, Inc. (MEIP)?
What is the 3-year average PE Ratio for MEI Pharma, Inc. (MEIP)?
What is the 5-year average PE Ratio for MEI Pharma, Inc. (MEIP)?
How does the current PE Ratio for MEI Pharma, Inc. (MEIP) compare to its historical average?